AbbVie cuts Q3 adjusted diluted EPS outlook to $3.73-$3.77 after $216 million acquired IPR&D, milestones expense

Bitget2026/10/05 20:09

AbbVie cut Q3 2026 adjusted diluted EPS guidance to USD 3.73–3.77 from USD 3.84–3.88, reflecting acquired IPR&D and milestones expense. It forecast USD 216 million of acquired IPR&D and milestones expense for the quarter, equal to a USD 0.11 per-share hit. Full-year 2026 adjusted diluted EPS guidance moved to USD 13.76–13.96 from USD 13.87–14.07 on the same USD 0.11 impact. Full-year acquired IPR&D and milestones expense expectation increased to USD 1.25 billion from USD 1.04 billion. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001551152-26-000030), on October 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

The value of cryptocurrency assets held by the U.S. government has shrunk by $16 billion from last year’s peak.

AiCoin•2026/10/11 03:23

Copper prices approach historic highs! UBS remains bullish: "Still most optimistic"

华尔街见闻•2026/10/11 01:57

A COVID Vaccine Stock on the S&P 500 Is Up 600% This Year

BeInCrypto•2026/10/10 22:48

The number of stablecoin holders on the Solana chain has surpassed 14 million.

AiCoin•2026/10/10 21:35